(2%) said that they did not feel they could refuse the test. After receiving their results, 368/379 (97%) women felt that they had made the right decision to be tested, but two carriers and three non-carriers had felt unhappy about testing. Couple testing with full disclosure was associated with lower anxiety levels two weeks after receiving the result for the pregnancy than stepwise testing and 82/278 (29%) noncarriers believed that they had no residual risk in relation to CF. Conclusions-The response from women accepting CF carrier testing was largely positive but a minority of women expressed concern about the test and the way it was offered and a substantial proportion of women were falsely reassured by their "negative" result. Higher levels of acceptance tended to occur Before the cloning of the cystic fibrosis (CF) gene,`3 CF carrier testing used linkage analysis and was thus restricted to people with a family history of CF. The subsequent development of PCR technology has made it feasible to offer CF carrier screening to the general population. Extending CF carrier testing beyond families with a family history has raised new issues. How do we know who would want such testing and should it be offered before pregnancy or during pregnancy, in primary care, in the antenatal clinic, or in some other setting? Testing in pregnancy has the advantage of approaching women at a time when they are receptive to the idea of screening.4-6 The identification of carrier couples before the end of the first trimester also allows couples the option of an early termination of an affected pregnancy. However, as this test is not specific to pregnancy, offering the test outside pregnancy has the advantage of enabling carrier couples to opt for counselling and consider their reproductive options without the anxiety of an ongoing pregnancy.79 It would seem preferable to offer testing before pregnancy,'0 but it is debatable how relevant this is thought to be by people with no previous CF family history. As well as the timing of the offer of the test, there is also the question of who should offer it: GPs, practice nurses, midwives, antenatal doctors, genetic coworkers, or public health workers.
Consideration should also be given to the method by which the test is offered. Wald" introduced "couple" testing in pregnancy whereby samples are obtained from both partners but only those couples where both partners were found to be carriers were informed of their carrier status. This method has the advantage of concentrating counselling resources on carrier couples and avoids the inevitable time of anxiety when a carrier must wait for the partner's sample to be tested as is the case in stepwise testing.' However, couple testing without full disclosure of the results does not allow for cascade testing in families where only one member of the couple has been found to be a carrier. Resolution of these questions has implications for the large number of new genetic screening tests which will probably become available.
This study concentrates on the acceptability of CF carrier testing to participating women and its immediate effect on individual subjects and couples.'2
Methods

SUBJECTS
Between July 1992 and February 1993, eight north west general practices with a combined list size of 42 000 began offering cystic fibrosis carrier screening to pregnant women at the first antenatal booking appointment. GPs were asked to participate for two years. Women were excluded from the study if they booked after 14 weeks' gestation or requested a termination of pregnancy at the booking appointment. As CF gene carrier frequency is highest in the white population (1 in 20 in the north west region of England), all but one of the practices selected had a low ethnic minority. However, as it was desirable for GPs to incorporate the offer of the test into their routine antenatal booking appointment, GPs were asked to offer the test to all eligible pregnant women, irrespective of their ethnic background. Appropriate corrections were made to carrier risks using the information provided by GPs about a person's ethnicity.
Women Women willing to complete a questionnaire were also asked to agree to be interviewed at home by a genetic associate (DS, NEH). The semistructured interview covered similar areas to the questionnaire but in more detail, as well as more sensitive questions about reproductive intentions that were thought to be inappropriate for inclusion in a postal questionnaire.
Results
Of the 623 women offered the test, 529 (84.9%) women accepted. Two hundred and sixty two were allocated to couple testing and 267 were allocated to stepwise testing. Forty two women declined the test and a further 52 women, having taken information and equipment away, then failed to return samples. In the stepwise group, 10 maternal carriers were found and all their partners were found to be at low risk. In the couple group, seven maternal carriers were found and nine paternal carriers, including the only carrier couple detected.4
All except practice 7 were asked to offer the test in the same way. Fig 1 indicates 
